+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sickle Cell Disease - Pipeline Review, H1 2020

  • ID: 5024770
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 271 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Editas Medicine Inc
  • Functional Fluidics LLC
  • Invenux LLC
  • Novartis AG
  • MORE
Sickle Cell Disease - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 11, 4, 26 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Editas Medicine Inc
  • Functional Fluidics LLC
  • Invenux LLC
  • Novartis AG
  • MORE
  • Introduction
  • Sickle Cell Disease - Overview
  • Sickle Cell Disease - Therapeutics Development
  • Sickle Cell Disease - Therapeutics Assessment
  • Sickle Cell Disease - Companies Involved in Therapeutics Development
  • Sickle Cell Disease - Drug Profiles
  • Sickle Cell Disease - Dormant Projects
  • Sickle Cell Disease - Discontinued Products
  • Sickle Cell Disease - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Sickle Cell Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Alkermes Plc, H1 2020
  • Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H1 2020
  • Sickle Cell Disease - Pipeline by Aruvant Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Axcella Health Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Beam Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by bluebird bio Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Sickle Cell Disease - Pipeline by C4X Discovery Holdings Plc, H1 2020
  • Sickle Cell Disease - Pipeline by Cannabis Science Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Cell Source Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Cetya Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by CRISPR Therapeutics AG, H1 2020
  • Sickle Cell Disease - Pipeline by CSL Ltd, H1 2020
  • Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Dystrogen Therapeutics SA, H1 2020
  • Sickle Cell Disease - Pipeline by Editas Medicine Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Emmaus Life Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Epidestiny Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Epizyme Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H1 2020
  • Sickle Cell Disease - Pipeline by ExCellThera Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Forma Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Functional Fluidics LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H1 2020
  • Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Glycan Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Homology Medicines Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Imara Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Invenux LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Medeor Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Merck & Co Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Micelle BioPharma Inc, H1 2020
  • Sickle Cell Disease - Pipeline by MimeTech Srl, H1 2020
  • Sickle Cell Disease - Pipeline by Modus Therapeutics AB, H1 2020
  • Sickle Cell Disease - Pipeline by Molecules For Health Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Novartis AG, H1 2020
  • Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H1 2020
  • Sickle Cell Disease - Pipeline by PHD Biosciences, H1 2020
  • Sickle Cell Disease - Pipeline by Phoenicia Biosciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Rare Partners Srl, H1 2020
  • Sickle Cell Disease - Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
  • Sickle Cell Disease - Pipeline by ReNeuroGen LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Secura Bio Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Tarus Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Trucode Gene Repair Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Vanguard Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Sickle Cell Disease - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Sickle Cell Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Agios Pharmaceuticals Inc
  • Alkermes Plc
  • Angiocrine Bioscience Inc
  • Annexin Pharmaceuticals AB
  • Aruvant Sciences Inc
  • Axcella Health Inc
  • Beam Therapeutics Inc
  • bluebird bio Inc
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings Plc
  • Cannabis Science Inc
  • Cell Source Inc
  • Cetya Therapeutics Inc
  • CRISPR Therapeutics AG
  • CSL Ltd
  • Cyclerion Therapeutics Inc
  • Dystrogen Therapeutics SA
  • Editas Medicine Inc
  • Emmaus Life Sciences Inc
  • Epidestiny Inc
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • ExCellThera Inc
  • Forma Therapeutics Inc
  • Fulcrum Therapeutics Inc
  • Functional Fluidics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Global Blood Therapeutics Inc
  • Glycan Therapeutics Inc
  • Hillhurst Biopharmaceuticals Inc
  • Homology Medicines Inc
  • Imara Inc
  • Intellia Therapeutics Inc
  • Invenux LLC
  • Medeor Therapeutics Inc
  • Merck & Co Inc
  • Micelle BioPharma Inc
  • MimeTech Srl
  • Modus Therapeutics AB
  • Molecules For Health Inc
  • Novartis AG
  • Oryzon Genomics SA
  • PHD Biosciences
  • Phoenicia Biosciences Inc
  • Rare Partners Srl
  • Regenacy Pharmaceuticals LLC
  • ReNeuroGen LLC
  • Sangamo Therapeutics Inc
  • Secura Bio Inc
  • Syros Pharmaceuticals Inc
  • Tarus Therapeutics Inc
  • Trucode Gene Repair Inc
  • Vanguard Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll